期刊文献+

盐酸安非他酮缓释片治疗焦虑症的临床观察 被引量:1

下载PDF
导出
摘要 目的观察盐酸安非他酮缓释片用于焦虑症临床治疗的疗效及不良反应,探讨安非他酮作为新型抗焦虑药物的应用价值。方法选取59例焦虑症患者,按照分段随机法分为安非他酮组(治疗组)30例及氟西汀组(对照组)29例,两组患者分别口服安非他酮片300mg/d及氟西汀片20mg/d,疗程均为6周。分别于治疗前后采用汉密尔顿焦虑量表(HAMA)及临床总体印象量表(CGI)评价两组疗效,并进行统计学分析及安全性分析。结果疗程结束后,治疗组及对照组的临床有效率分别为66.7%、65.6%(P>0.05),HAMA减分值分别为(8.80±5.59)、(8.79±5.31)(P>0.05),临床总体印象降低值分别为(2.60±0.86)、(2.93±1.03)(P>0.05),不良事件发生率分别为63.3%,48.3%(P>0.05),未发生严重不良事件,各项指标差异均无统计学意义。结论盐酸安非他酮用于焦虑症的治疗具有与氟西汀相近的疗效及安全性,可作为一种新型抗焦虑药物用于临床治疗。
出处 《中国医药指南》 2012年第21期114-116,共3页 Guide of China Medicine
  • 相关文献

参考文献8

  • 1韩春美,韩勇.盐酸安非他酮治疗抑郁与焦虑障碍的临床观察[J].中国医药指南,2008,6(21):32-33. 被引量:2
  • 2Trotter B,Kelsberg G,St-Anna L,et al.How should we treat majordepression combined with anxiety?[J].J Fam Pract,2007,56(4):306-308.
  • 3Yatham LN,Kennedy SH,Schaffer A,et al.Canadian Network forMood and Anxiety Treatments(CANMAT)and InternationalSociety for Bipolar Disorders(ISBD)collaborative updateof CANMAT guidelines for the management of patients withbipolar disorder:update 2009[J].Bipolar Disorders,2009,11(3):225-255.
  • 4Papakostas GI,Worthington JJ,Iosifescu DV,et al.The combinationof duloxetine and bupropion for treatment-resistant majordepressive disorder[J].Depress Anxiety,2006,23(3):178-181.
  • 5Papakostas GI,Trivedi MH,Alpert JE,et al.Efficacy of bupropionand the selective serotonin reuptake inhibitors in the treatment ofanxiety symptoms in major depressive disorder:a meta-analysis ofindividual patient data from 10 double-blind,randomized clinicaltrials[J].J Psychiatric Res,2008,42(2):134-140.
  • 6吴彦,沈一峰,李华芳,孙学礼,许秀峰,高成阁,顾牛范.安非他酮缓释片治疗抑郁伴随焦虑症状的随机双盲临床研究[J].上海精神医学,2009,21(5):285-288. 被引量:2
  • 7孟焱,李战文,张红梅.安非他酮与米氮平治疗抑郁症伴有焦虑疗效比较[J].职业与健康,2008,24(20):2226-2227. 被引量:2
  • 8Bailey J,Waters S.Acute psychosis after bupropion treatment in a healthy 28-year-old woman[J].J Am Board Fam Med,2008,21(3):244-245.

二级参考文献22

  • 1李华芳,赵靖平,况伟宏,姚培芬,陈晋东,孙学礼,顾牛范.安非他酮缓释片治疗抑郁症72例的随机双盲双模拟多中心临床研究[J].中国新药与临床杂志,2005,24(8):614-618. 被引量:14
  • 2刘文英,廖春平,高欢.米氮平与帕罗西汀治疗抑郁症对照研究[J].临床心身疾病杂志,2007,13(3):200-202. 被引量:12
  • 3Tomarken A J, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord, 2004, 78(3) : 235 -241.
  • 4Glod CA, Lynch A, Flynn E, et al. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs, 2003, 16 (3) : 123 -130.
  • 5Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31 - item Hamilton rating scale for depression. Psychopharmacol Bull, 2003,37 (2) : 67 -78.
  • 6Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained - release in patients with major depression treated for 52 weeks. Clin Ther, 2002, 24(4) : 662 -672.
  • 7Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiat, 2002, 51 (9) : 753 - 761.
  • 8Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta - analysis of individual patient data from 10 double - blind, randomized clinical trials. J Psyehiatr Res, 2008, 42 (2) : 134 - 140.
  • 9Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained - release bupropion in depression: results of three clinical trials. Clin Ther, 1999, 21(3) : 454 -463.
  • 10[1]Corcoran C,Wong ML,O'Keane V.Bupropion in the management of apathy[J].Psychopharmacol,2004,18(1):133-135.

共引文献3

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部